Ergomed Aktie kaufenswert? (Seite 2)
eröffnet am 01.12.16 16:57:13 von
neuester Beitrag 04.09.23 10:24:12 von
neuester Beitrag 04.09.23 10:24:12 von
Beiträge: 415
ID: 1.242.462
ID: 1.242.462
Aufrufe heute: 0
Gesamt: 19.692
Gesamt: 19.692
Aktive User: 0
ISIN: GB00BN7ZCY67 · WKN: A117XM
15,480
EUR
+0,06 %
+0,010 EUR
Letzter Kurs 08.11.23 Lang & Schwarz
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,5800 | +922,86 | |
| 1,0400 | +48,57 | |
| 0,5400 | +38,46 | |
| 5,4000 | +27,06 | |
| 1,9900 | +26,75 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 24,000 | -20,00 | |
| 28,18 | -32,62 | |
| 100,00 | -37,50 | |
| 3,6400 | -38,62 | |
| 0,5660 | -40,42 |
Beitrag zu dieser Diskussion schreiben
Feedback
Navigating the Path Towards Decentralized Trials in Oncology: From Technology to AI", this hot topic webinar will occur on 18 November 2021.
https://www.bigmarker.com/bioalliance-video-network/Navigati…
https://www.bigmarker.com/bioalliance-video-network/Navigati…
Ergomed : Debra Kientop appointed as the new Vice President of Therapeutic Strategy for Oncology
https://www.marketscreener.com/quote/stock/ERGOMED-PLC-16917…
https://www.marketscreener.com/quote/stock/ERGOMED-PLC-16917…
US is now the biggest market in the mix
Ergomed has released its full H121 results. H121 revenue numbers were included in the trading update in July 2021, while the full accounts released last week provided details on profits. In the trading update, management also guided that FY21 adjusted EBITDA would be materially ahead of market expectations, which has since been discounted in the share price, hence last week’s announcement delivered no surprises. However, the key takeaway for us was that overall operational momentum continues to be strong, including the first three months of H221 (following the already stellar performance in FY20). In H121, Ergomed has also launched its expansion into the Japanese market. We have slightly increased our valuation to £751m or 1,536p/share (from 1,445p/share).
https://www.edisongroup.com/publication/us-is-now-the-bigges…
Ergomed has released its full H121 results. H121 revenue numbers were included in the trading update in July 2021, while the full accounts released last week provided details on profits. In the trading update, management also guided that FY21 adjusted EBITDA would be materially ahead of market expectations, which has since been discounted in the share price, hence last week’s announcement delivered no surprises. However, the key takeaway for us was that overall operational momentum continues to be strong, including the first three months of H221 (following the already stellar performance in FY20). In H121, Ergomed has also launched its expansion into the Japanese market. We have slightly increased our valuation to £751m or 1,536p/share (from 1,445p/share).
https://www.edisongroup.com/publication/us-is-now-the-bigges…
Ergomed reveal 'great progress on delivering on strategy in first half of 2021'
https://www.proactiveinvestors.co.uk/companies/news/961530/e…
https://www.proactiveinvestors.co.uk/companies/news/961530/e…
Ergomed revenue rises as it integrates acquisitions
https://www.sharecast.com/news/aim-bulletin/ergomed-revenue-…
https://www.sharecast.com/news/aim-bulletin/ergomed-revenue-…
Trading Spotlight
Ergomed Interim results
Total revenue growth of 38.8% over H1 2020 to £56.0 million (up 48.1% in constant currency*)
djusted EBITDA of £12.1 million up 33.0%
Basic adjusted earnings per share of 16.8p, up 48.7%
Service fee revenue growth of 29.3% (11.1% on a like-for-like basis, 18.2% in constant currency*)
CRO revenue up 90.2% over H1 2020 to £27.2 million, with like-for-like growth of 16.1% (up 24.5% in constant currency*)
Net new sales awards in H1 2021 increased by 50.8% over H1 2020
Growth in order book maintained - up 18.0% since 1 January 2021 (£193.0 million) and up 50.5% on prior year to £227.8 million, providing high visibility into H2 2021 and beyond
Continued international expansion with growing presence in the USA
North America revenues up 70.8% to £35.5 million with recent acquisitions Ashfield Pharmacovigilance and MedSource fully integrated
Cash balance increased to £24.6 million and debt free
https://www.proactiveinvestors.co.uk/LON:ERGO/Ergomed-PLC/rn…
Total revenue growth of 38.8% over H1 2020 to £56.0 million (up 48.1% in constant currency*)
djusted EBITDA of £12.1 million up 33.0%
Basic adjusted earnings per share of 16.8p, up 48.7%
Service fee revenue growth of 29.3% (11.1% on a like-for-like basis, 18.2% in constant currency*)
CRO revenue up 90.2% over H1 2020 to £27.2 million, with like-for-like growth of 16.1% (up 24.5% in constant currency*)
Net new sales awards in H1 2021 increased by 50.8% over H1 2020
Growth in order book maintained - up 18.0% since 1 January 2021 (£193.0 million) and up 50.5% on prior year to £227.8 million, providing high visibility into H2 2021 and beyond
Continued international expansion with growing presence in the USA
North America revenues up 70.8% to £35.5 million with recent acquisitions Ashfield Pharmacovigilance and MedSource fully integrated
Cash balance increased to £24.6 million and debt free
https://www.proactiveinvestors.co.uk/LON:ERGO/Ergomed-PLC/rn…
Pharmacovigilance Outsourcing Market Size to Reach $9.65 Bn, Globally, by 2030 at 14.6% CAGR: Allied Market Research
https://www.prnewswire.com/news-releases/pharmacovigilance-o…
https://www.prnewswire.com/news-releases/pharmacovigilance-o…
Guildford, UK - 18 August 2021 : Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that on 17 August 2021, in order to meet demand from new and existing investors, Dr Miroslav Reljanović, Executive Chairman of Ergomed, and Richard Barfield, Chief Financial Officer of Ergomed, sold 1,200,000 ordinary shares of 1p each in the Company ("Ordinary Shares") and 50,000 Ordinary Shares respectively at a price of 1200 pence per share.
https://www.investegate.co.uk/ergomed-plc--ergo-/rns/directo…
https://www.investegate.co.uk/ergomed-plc--ergo-/rns/directo…
Sorry - stimmt 
Ergomed deliver double digit revenue growth as well as operational progress (27.07.2021)
Ergomed PLC's (LON:ERG) Richard Barfield delivers the company's trading update for the first half of 2021.
Among the highlights include total revenues for the period of £56.0 million, up from £40.4 million for the same period last year, an increase of 38.8%.
As well as delivering strong results and operational progress during the first half of the year, the firm has concluded their transition to a services-based business model and rapidly integrated recent acquisitions as Barfield explains.
Growth in the pharmacovigilance business has continued and the CRO business saw a substantial revenue increase supported by the recent US acquisition.
Ergomed deliver double digit revenue growth as well as operational progress (27.07.2021)
Ergomed PLC's (LON:ERG) Richard Barfield delivers the company's trading update for the first half of 2021.
Among the highlights include total revenues for the period of £56.0 million, up from £40.4 million for the same period last year, an increase of 38.8%.
As well as delivering strong results and operational progress during the first half of the year, the firm has concluded their transition to a services-based business model and rapidly integrated recent acquisitions as Barfield explains.
Growth in the pharmacovigilance business has continued and the CRO business saw a substantial revenue increase supported by the recent US acquisition.
Antwort auf Beitrag Nr.: 69.018.875 von H2Future am 11.08.21 11:01:21
Das ist das Video vom letzten Jahr!
Zitat von H2Future: Ergomed - executive interview
Das ist das Video vom letzten Jahr!
Durchsuchen
